Absci Expands ABS-201 Scientific Advisory Board with Addition of Leading Dermatology Experts Dr. Rodney Sinclair and Dr. David Goldberg
Absci (Nasdaq: ABSI) has strengthened its ABS-201 Scientific Advisory Board by adding two prominent dermatology experts, Dr. Rodney Sinclair and Dr. David Goldberg. The experts will guide the development of ABS-201, an AI-designed therapeutic antibody for androgenetic alopecia treatment.
ABS-201 targets prolactin receptors to stimulate hair follicle regeneration and has shown superior hair regrowth compared to minoxidil in preclinical mouse models. The company plans to initiate Phase 1/2a clinical trials in early 2026, with initial proof-of-concept data expected in H2 2026.
The condition affects approximately 80 million Americans, with current FDA-approved treatments showing limited efficacy and notable side effects. Both new advisors bring extensive experience in dermatology and hair loss research, with Dr. Sinclair having authored over 1,000 publications and Dr. Goldberg having participated in the original Minoxidil trials.
Absci (Nasdaq: ABSI) ha rafforzato il suo ABS-201 Scientific Advisory Board nominando due eminenti esperti in dermatologia, Dr. Rodney Sinclair e Dr. David Goldberg. I nuovi consulenti guideranno lo sviluppo di ABS-201, un anticorpo terapeutico progettato con l'aiuto dell'IA per il trattamento dell'alopecia androgenetica.
ABS-201 agisce sui recettori della prolattina per stimolare la rigenerazione dei follicoli piliferi e, nei modelli murini preclinici, ha dimostrato una crescita dei capelli superiore al minoxidil. L'azienda prevede di avviare le prove cliniche di Fase 1/2a all'inizio del 2026, con i primi dati di proof-of-concept attesi nella seconda metà del 2026.
La patologia interessa circa 80 milioni di americani e le terapie attualmente approvate dalla FDA presentano efficacia limitata e effetti collaterali rilevanti. Entrambi i nuovi consiglieri vantano una lunga esperienza nella ricerca sulla dermatologia e la perdita di capelli: il Dr. Sinclair ha pubblicato oltre 1.000 lavori, mentre il Dr. Goldberg ha partecipato agli studi originali sul Minoxidil.
Absci (Nasdaq: ABSI) ha reforzado su ABS-201 Scientific Advisory Board incorporando a dos destacados expertos en dermatología, Dr. Rodney Sinclair y Dr. David Goldberg. Ambos asesorarán el desarrollo de ABS-201, un anticuerpo terapéutico diseñado mediante IA para el tratamiento de la alopecia androgenética.
ABS-201 se dirige a los receptores de prolactina para estimular la regeneración de los folículos pilosos y ha mostrado en modelos preclínicos murinos una mayor regeneración capilar que el minoxidil. La compañía planea iniciar los ensayos clínicos de Fase 1/2a a principios de 2026, con los primeros datos de prueba de concepto esperados en la segunda mitad de 2026.
La afección afecta a aproximadamente 80 millones de estadounidenses, y los tratamientos aprobados por la FDA hasta ahora presentan eficacia limitada y efectos secundarios considerables. Ambos asesores aportan amplia experiencia en dermatología y en investigación sobre pérdida de cabello: el Dr. Sinclair ha publicado más de 1.000 trabajos y el Dr. Goldberg participó en los ensayos originales del Minoxidil.
Absci (나스닥: ABSI)는 ABS-201 과학 자문위원회에 피부과 분야의 저명한 전문가 Dr. Rodney Sinclair와 Dr. David Goldberg를 영입해 위원회를 강화했습니다. 두 전문가는 안드로겐성 탈모 치료를 위한 AI 설계 치료 항체인 ABS-201 개발을 지도합니다.
ABS-201은 프로락틴 수용체를 표적으로 삼아 모낭 재생을 촉진하며, 전임상 마우스 모델에서 미녹시딜보다 우수한 모발 재성장을 보였습니다. 회사는 2026년 초에 1/2a상 임상시험을 시작할 계획이며, 개념 증명 초기 데이터는 2026년 하반기에 나올 것으로 예상됩니다.
이 질환은 약 8천만 명의 미국인에게 영향을 미치며, 현재 FDA 승인 치료제들은 효과가 제한적이고 부작용이 큽니다. 신규 자문위원 둘 다 피부과 및 탈모 연구에 대한 풍부한 경험을 가지고 있으며, Sinclair 박사는 1,000편 이상의 논문을 저술했고 Goldberg 박사는 원래 미녹시딜 임상에 참여했습니다.
Absci (Nasdaq: ABSI) a renforcé son ABS-201 Scientific Advisory Board en intégrant deux experts en dermatologie de renom, Dr. Rodney Sinclair et Dr. David Goldberg. Ces spécialistes accompagneront le développement d'ABS-201, un anticorps thérapeutique conçu par IA pour traiter l'alopécie androgénétique.
ABS-201 cible les récepteurs de la prolactine pour stimuler la régénération des follicules pileux et a montré dans des modèles murins précliniques une repousse des cheveux supérieure au minoxidil. La société prévoit de lancer les essais cliniques de phase 1/2a début 2026, les premiers résultats de preuve de concept étant attendus au second semestre 2026.
Cette affection touche environ 80 millions d'Américains et les traitements actuellement approuvés par la FDA présentent une efficacité limitée et des effets secondaires notables. Les deux nouveaux conseillers apportent une vaste expérience en dermatologie et en recherche sur la perte de cheveux : le Dr. Sinclair a signé plus de 1 000 publications et le Dr. Goldberg a participé aux essais initiaux du minoxidil.
Absci (Nasdaq: ABSI) hat sein ABS-201 Scientific Advisory Board durch die Ernennung zweier führender Dermatologie-Experten, Dr. Rodney Sinclair und Dr. David Goldberg, verstärkt. Die Experten werden die Entwicklung von ABS-201 leiten, einem KI-designten therapeutischen Antikörper zur Behandlung der androgenetischen Alopezie.
ABS-201 zielt auf Prolaktinrezeptoren ab, um die Regeneration der Haarfollikel zu stimulieren, und zeigte in präklinischen Mausmodellen eine überlegene Haarneubildung gegenüber Minoxidil. Das Unternehmen plant, Anfang 2026 Phase-1/2a-Studien zu starten, wobei die ersten Proof-of-Concept-Daten für H2 2026 erwartet werden.
Die Erkrankung betrifft etwa 80 Millionen Amerikaner, und die derzeit von der FDA zugelassenen Therapien zeigen begrenzte Wirksamkeit und teils erhebliche Nebenwirkungen. Beide neuen Berater bringen umfangreiche Erfahrung in Dermatologie und Haarforschungen mit: Dr. Sinclair hat über 1.000 Publikationen verfasst, Dr. Goldberg war an den ursprünglichen Minoxidil-Studien beteiligt.
- Promising preclinical results showing superior efficacy compared to existing treatment minoxidil
- Phase 1/2a clinical trials scheduled to begin in early 2026
- Addition of two world-renowned experts strengthens scientific advisory board
- Large market opportunity with 80 million affected Americans
- Clinical trials won't begin until 2026, indicating a long path to potential commercialization
- Efficacy in humans yet to be proven despite promising preclinical results
Insights
Absci strengthens its hair loss program with top dermatology experts as ABS-201 advances toward 2026 clinical trials with promising preclinical data.
This announcement represents a significant development for Absci's clinical pipeline strategy. The addition of Drs. Sinclair and Goldberg to the Scientific Advisory Board for ABS-201 brings substantial credibility and expertise to Absci's hair regrowth program. Both experts bring impressive credentials - Dr. Sinclair with over 1000 publications and Dr. Goldberg with experience in the original Minoxidil trials - providing valuable clinical development guidance as ABS-201 approaches Phase 1/2a trials.
The program targets an attractive market opportunity with approximately 80 million Americans affected by androgenetic alopecia and limited effective treatment options. Current FDA-approved treatments (minoxidil and finasteride) have notable limitations in efficacy and side effects, creating a clear unmet need.
ABS-201's novel mechanism targeting prolactin receptors differentiates it from existing therapies. Preclinical data showing statistically significant superior hair regrowth compared to minoxidil provides early validation of this approach. The company has established a clear development timeline with Phase 1/2a trials beginning in early 2026 and initial proof-of-concept data expected in H2 2026.
The expanded advisory board positions Absci to leverage AI-driven drug discovery capabilities while ensuring rigorous clinical development oversight, potentially accelerating their path to market with a differentiated therapeutic option for a condition with substantial quality-of-life impact.
World-renowned experts will guide the clinical development of ABS-201, a therapeutic antibody entering clinical trials for the treatment of androgenetic alopecia.
VANCOUVER, Wash. and NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a clinical-stage biotech company advancing breakthrough therapeutics with generative AI, today announced that world-renowned dermatologists Dr. Rodney Sinclair and Dr. David Goldberg have joined its ABS-201 Scientific Advisory Board. They will guide the scientific and clinical development of ABS-201, Absci’s flagship, AI-designed therapeutic program for androgenetic alopecia.
Androgenetic alopecia, commonly known as male-pattern or female-pattern hair loss, affects approximately 80 million Americans alone. The condition causes crown balding and receding hairlines in men, and progressive hair thinning in women. Currently, the only FDA-approved treatments—minoxidil and finasteride—show limited efficacy and notable side effects, leaving patients with limited therapeutic options.
ABS-201 represents a novel therapeutic approach targeting prolactin receptors to stimulate hair follicle regeneration and promote durable hair regrowth as demonstrated in in vivo studies. In preclinical studies, the antibody demonstrated statistically significant superior hair regrowth compared to minoxidil in pre-clinical mouse models. Phase 1/2a clinical trials are planned to begin in early 2026, with initial proof-of-concept data expected in the second half of 2026.
"Dr. Sinclair and Dr. Goldberg bring world-class expertise to our hair-regrowth program,” said Sean McClain, Founder and CEO of Absci. “Their deep understanding of androgenetic alopecia and its treatment challenges will be invaluable as we rapidly advance ABS-201 toward clinical validation as a potential best-in-class therapy."
Dr. Rodney Sinclair, MBBS, MD, FACD, is the Professor of Dermatology at the University of Melbourne and Director of Sinclair Dermatology in Melbourne. He is a world-renowned expert in hair loss, with over three decades dedicated to research, clinical practice, and patient advocacy. Dr. Sinclair has authored over 1000 publications including contributions to key textbooks in dermatology and hair disorders.
"Having researched hair loss for over three decades, I've seen the substantial impact androgenetic alopecia has on patients' quality of life and self-esteem," said Dr. Sinclair. "ABS-201 has a novel mechanism of action and a promising preclinical profile with the potential for a durable therapy to address a condition where all currently available treatments require continuous usage. I look forward to building on Absci’s momentum and innovation."
Dr. David J. Goldberg, MD, JD, has nearly four decades of clinical dermatology experience, with particular expertise in laser therapy and cosmetic dermatology. He is Clinical Professor of Dermatology at the Icahn School of Medicine at Mount Sinai and has performed pivotal research studies in dermatology and hair loss including the original Minoxidil trials. Dr. Goldberg has published more than 200 academic papers and contributed to over 15 textbooks on hair restoration and dermatology. He has served as a member of the Board of Directors of the American Academy of Dermatology and the American Society for Dermatologic Surgery.
“Having been involved in research on hair loss for many years, including the original minoxidil trials, low-level light and PRP treatments, I’ve seen both the achievements and limitations of current therapies. ABS-201’s approach is rooted in sound science and early data that show real promise. I’m honored to work with Absci’s talented team to help bring innovative, effective solutions to patients suffering from androgenetic alopecia,” said Dr. Goldberg
With the expansion of the ABS-201 Scientific Advisory Board, Drs. Sinclair and Goldberg join a distinguished roster of renowned experts in dermatology and hair restoration, including Drs. Anthony Rossi, Maria Hordinsky, Ken Washenik among others.
About Absci
Absci is advancing the future of drug discovery with generative design to create better biologics for patients, faster. Our Integrated Drug Creation™ platform combines cutting-edge AI models with a synthetic biology data engine, enabling the rapid design of innovative therapeutics that address challenging therapeutic targets. Absci’s approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Each cycle refines our data and strengthens our models, facilitating rapid innovation and enhancing the precision of our therapeutic designs. Alongside collaborations with top pharmaceutical, biotech, tech, and academic leaders, Absci is advancing its own pipeline of AI designed therapeutics. These include ABS-101, a potentially best-in-class antibody to treat inflammatory bowel disease (IBD), as well as other indications, and ABS-201, a groundbreaking innovation in hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern baldness. Absci is headquartered in Vancouver, WA, with an AI Research Lab in New York City, and Innovation Center in Switzerland. Learn more at www.absci.com or follow us on LinkedIn (@absci), X (@Abscibio) and YouTube.
Absci Forward-Looking Statements
Certain statements in this press release that are not historical facts are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements containing the words “will,” “pursues,” “anticipates,” “plans,” “believes,” “forecast,” “potential,” “goal,” “estimates,” “extends,” “expects,” and “intends,” or similar expressions. We intend these forward-looking statements, including statements regarding our expectations related to business operations, portfolio strategy, financial performance, and results of operations, our expectations and guidance related to the success of our partnerships, the gross use of cash, cash equivalents, and short-term investments, including revised guidance, our projected cash usage, needs, and runway, our expectations regarding the signing and number of additional partners and number of programs included in such partnerships, our technology development efforts and the application of those efforts, including for generalizing our platform, accelerating drug development timelines, improving the economics of drug discovery by lowering costs, and increasing the probability of success for drug development, our ability to execute with our partners to create differentiated antibody therapeutic candidates in an efficient manner, create and execute a successful development and commercialization strategy related to such candidates with current or future partners, and design and develop differentiated therapeutics to treat disease with unmet need, our ability to market our platform technologies to potential partners, and our internal asset programs, including our clinical development strategy, the progress and timing for various stages of development including advancement to lead stage, completion of pre-clinical studies, candidate selection, IND enabling studies, initiating clinical trials and the generation and disclosure of data related to these programs, the translation of preclinical results and data into product candidates, and the significance of preclinical results, including in comparison to competitor molecules and in leading to differentiated clinical efficacy or product profiles, to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, and we make this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies, and prospects, which are based on the information currently available to us and on assumptions we have made. We can give no assurance that the plans, intentions, expectations, or strategies will be attained or achieved, and, furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control, including, without limitation, risks and uncertainties relating to obtaining and maintaining necessary approvals from the FDA and other regulatory authorities, replicating in clinical trials promising or positive results observed in preclinical studies, our dependence on third parties to support our internal asset programs, including for the manufacture and supply of preclinical and clinical supplies of our product candidates or components thereof, our ability to effectively collaborate on research, drug discovery and development activities with our partners or potential partners, our existing and potential partners’ ability and willingness to pursue the development and commercialization of programs or product candidates under the terms of our partnership agreements, and overall market conditions and regulatory developments that may affect our and our partners’ activities under these agreements, along with those risks set forth in our most recent periodic report filed with the U.S. Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the U.S. Securities and Exchange Commission. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise.
Absci Media Contact
Absci Investor Contact
Alex KhanVP, Finance & Investor Relations
FAQ
What is ABS-201 and how does it treat hair loss?
When will Absci (ABSI) begin clinical trials for ABS-201?
Who are the new members of Absci's ABS-201 Scientific Advisory Board?
How many people are affected by androgenetic alopecia in the US?
What advantages could ABS-201 have over existing hair loss treatments?
